Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
08
09
2019
accepted:
05
02
2020
revised:
30
01
2020
pubmed:
27
2
2020
medline:
31
12
2020
entrez:
27
2
2020
Statut:
ppublish
Résumé
High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian carcinoma, associated with poor clinical outcome and metastatic disease. Although metastatic processes are becoming more understandable, the genomic landscape and metastatic progression in HGSOC has not been elucidated. Multi-region whole-exome sequencing was performed on HGSOC primary tumours and their metastases (n = 33 tumour regions) from six patients. The resulting somatic variants were analysed to delineate tumour evolution and metastatic dissemination, and to compare the repertoire of events between primary HGSOC and metastasis. All cases presented branching evolution patterns in primary HGSOC, with three cases further showing parallel evolution in which different mutations on separate branches of a phylogenetic tree converge on the same gene. Furthermore, linear metastatic progression was observed in 67% of cases with late dissemination, in which the metastatic tumour mostly acquires the same mutational process active in primary tumour, and parallel metastatic progression, with early dissemination in the remaining 33.3% of cases. Metastatic-specific SNVs were further confirmed as late dissemination events. We also found the involvement of metastatic-specific driver events in the Wnt/β-catenin pathway, and identified potential clinically actionable events in individual patients of the metastatic HGSOC cohort. This study provides deeper insights into clonal evolution and mutational processes that can pave the way to new therapeutic targets.
Sections du résumé
BACKGROUND
High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian carcinoma, associated with poor clinical outcome and metastatic disease. Although metastatic processes are becoming more understandable, the genomic landscape and metastatic progression in HGSOC has not been elucidated.
METHODS
Multi-region whole-exome sequencing was performed on HGSOC primary tumours and their metastases (n = 33 tumour regions) from six patients. The resulting somatic variants were analysed to delineate tumour evolution and metastatic dissemination, and to compare the repertoire of events between primary HGSOC and metastasis.
RESULTS
All cases presented branching evolution patterns in primary HGSOC, with three cases further showing parallel evolution in which different mutations on separate branches of a phylogenetic tree converge on the same gene. Furthermore, linear metastatic progression was observed in 67% of cases with late dissemination, in which the metastatic tumour mostly acquires the same mutational process active in primary tumour, and parallel metastatic progression, with early dissemination in the remaining 33.3% of cases. Metastatic-specific SNVs were further confirmed as late dissemination events. We also found the involvement of metastatic-specific driver events in the Wnt/β-catenin pathway, and identified potential clinically actionable events in individual patients of the metastatic HGSOC cohort.
CONCLUSIONS
This study provides deeper insights into clonal evolution and mutational processes that can pave the way to new therapeutic targets.
Identifiants
pubmed: 32099096
doi: 10.1038/s41416-020-0763-4
pii: 10.1038/s41416-020-0763-4
pmc: PMC7156387
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1219-1230Références
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J. & Jemal, A. Global cancer statistics, 2012. CA: Cancer J. Clin. 65, 87–108 (2015).
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945–956 (2016).
pubmed: 26707054
pmcid: 4779792
Bowtell, D. D., Bohm, S., Ahmed, A. A., Aspuria, P. J., Bast, R. C. Jr., Beral, V. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).
pubmed: 26493647
pmcid: 4892184
McPherson, A., Roth, A., Laks, E., Masud, T., Bashashati, A., Zhang, A. W. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758–767 (2016).
pubmed: 27182968
Klein, C. A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302–312 (2009).
pubmed: 19308069
Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053–1064 (2010).
pubmed: 20651229
pmcid: 2928939
Kurman, R. J. Blaustein’s Pathology of the Female Genital Tract (Springer Science & Business Media, 2013).
Bao, L., Messer, K., Schwab, R., Harismendy, O., Pu, M., Crain, B. et al. Mutational profiling can establish clonal or independent origin in synchronous bilateral breast and other tumors. PLoS ONE 10, e0142487 (2015).
pubmed: 26554380
pmcid: 4640562
Khalique, L., Ayhan, A., Whittaker, J. C., Singh, N., Jacobs, I. J., Gayther, S. A. et al. The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int. J. Cancer 124, 1579–1586 (2009).
pubmed: 19123469
Micci, F., Haugom, L., Ahlquist, T., Abeler, V. M., Trope, C. G., Lothe, R. A. et al. Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution. J. Oncol. 2010, e646340 (2010).
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
pubmed: 24487277
pmcid: 4636053
Turajlic, S. & Swanton, C. Metastasis as an evolutionary process. Science 352, 169–175 (2016).
pubmed: 27124450
Naxerova, K. & Jain, R. K. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat. Rev. Clin. Oncol. 12, 258–272 (2015).
pubmed: 25601447
Schwarz, R. F., Ng, C. K., Cooke, S. L., Newman, S., Temple, J., Piskorz, A. M. et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 12, e1001789 (2015).
pubmed: 25710373
pmcid: 4339382
Kim, S., Han, Y., Kim, S. I., Kim, H. S., Kim, S. J. & Song, Y. S. Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis. Oncol. 2, 20 (2018).
pubmed: 30246154
pmcid: 6141595
Kroigard, A. B., Larsen, M. J., Laenkholm, A. V., Knoop, A. S., Jensen, J. D., Bak, M. et al. Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis. Oncotarget 6, 5634–5649 (2015).
pubmed: 25730902
pmcid: 4467391
McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15–26 (2015).
pubmed: 25584892
Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. Oncogene 36, 1461–1473 (2017).
Popic, V., Salari, R., Hajirasouliha, I., Kashef-Haghighi, D., West, R. B. & Batzoglou, S. Fast and scalable inference of multi-sample cancer lineages. Genome Biol. 16, 91 (2015).
pubmed: 25944252
pmcid: 4501097
Corvigno, S., Wisman, G. B., Mezheyeuski, A., van der Zee, A. G., Nijman, H. W., Avall-Lundqvist, E. et al. Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: inter- and intra-patient heterogeneity and impact on survival. Oncotarget 7, 18573–18584 (2016).
pubmed: 26918345
pmcid: 4951310
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385 e318 (2018).
pubmed: 6029450
pmcid: 6029450
Yang, S. Y. C., Lheureux, S., Karakasis, K., Burnier, J. V., Bruce, J. P., Clouthier, D. L. et al. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med. 10, 81 (2018).
pubmed: 30382883
pmcid: 6208125
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Horswell, S., Chambers, T. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 173, 595–610 e511 (2018).
pubmed: 29656894
pmcid: 5938372
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
pubmed: 28445112
Hosseini H., Obradović, M. M. S., Hoffmann, M., Harper, K. L., Sosa, M. S., Werner-Klein, M. et al. Early dissemination seeds metastasis in breast cancer. Nature 540, 552–558 (2016).
pubmed: 27974799
pmcid: 5390864
Inno, A., Di Noia, V., D’Argento, E., Modena, A. & Gori, S. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. Transl. Lung Cancer Res. 5, 599–609 (2016).
pubmed: 28149755
pmcid: 5233886
Tan, I. B., Malik, S., Ramnarayanan, K., McPherson, J. R., Ho, D. L., Suzuki, Y. et al. High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biol. 16, 32 (2015).
pubmed: 25808843
pmcid: 4365969
Gerstung, M., Beisel, C., Rechsteiner, M., Wild, P., Schraml, P., Moch, H. et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat. Commun. 3, 811 (2012).
pubmed: 22549840
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880–886 (2015).
pubmed: 25999502
pmcid: 4471149
Ishaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D. et al. Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nat. Commun. 9, 4782 (2018).
pubmed: 30429477
pmcid: 6235880
Yap, T. A., Sandhu, S. K., Carden, C. P. & de Bono, J. S. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 61, 31–49 (2011).
pubmed: 21205831
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56 (2010).
pubmed: 20229506
pmcid: 3262968
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 8, 1093 (2017).
pubmed: 29061967
pmcid: 5653668
Garziera, M., Cecchin, E., Canzonieri, V., Sorio, R., Giorda, G., Scalone, S. et al. Identification of novel somatic TP53 mutations in patients with high-grade serous ovarian cancer (HGSOC) using next-generation sequencing (NGS). Int. J. Mol. Sci. 19; https://doi.org/10.3390/ijms19051510 (2018).
Padmanabhan, A., Candelaria, N., Wong, K. K., Nikolai, B. C., Lonard, D. M., O’Malley, B. W. et al. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat. Commun. 9, 1270 (2018).
pubmed: 29593334
pmcid: 5871815
Arend, R. C., Londono, A. I., Montgomery, A. M., Smith, H. J., Dobbin, Z. C., Katre, A. A. et al. Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma. Mol. Cancer Res. 16, 813–824 (2018).
pubmed: 29523763
pmcid: 6497146
Lipinski, K. A., Barber, L. J., Davies, M. N., Ashenden, M., Sottoriva, A. & Gerlinger, M. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer 2, 49–63 (2016).
pubmed: 26949746
pmcid: 4756277
Casás-Selves, M. & DeGregori, J. How cancer shapes evolution and how evolution shapes cancer. Evolution: Educ. Outreach 4, 624 (2011).
Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238–244 (2016).
pubmed: 26780609
pmcid: 4934603
Sottoriva, A., Kang, H., Ma, Z., Graham, T. A., Salomon, M. P., Zhao, J. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209–216 (2015).
pubmed: 25665006
pmcid: 4575589
Amirouchene-Angelozzi, N., Swanton, C. & Bardelli, A. Tumor evolution as a therapeutic target. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-17-0343 (2017).
Jimenez-Sanchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927–938 e920 (2017).
pubmed: 28841418
pmcid: 5589211
Saito, T., Niida, A., Uchi, R., Hirata, H., Komatsu, H., Sakimura, S. et al. A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nat. Commun. 9, 2884 (2018).
pubmed: 30038269
pmcid: 6056524
Vermaat, J. S., Nijman, I. J., Koudijs, M. J., Gerritse, F. L., Scherer, S. J., Mokry, M. et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin. Cancer Res. 18, 688–699 (2012).
pubmed: 22173549
Wu, X., Northcott, P. A., Dubuc, A., Dupuy, A. J., Shih, D. J., Witt, H. et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529–533 (2012).
pubmed: 22343890
pmcid: 3288636
Zhai, W., Lim, T. K., Zhang, T., Phang, S. T., Tiang, Z., Guan, P. et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun. 8, 4565 (2017).
pubmed: 28240289
pmcid: 5333358
Cairns, J. Mutation selection and the natural history of cancer. Nature 255, 197–200 (1975).
pubmed: 1143315
Wang, D., Niu, X., Wang, Z., Song, C. L., Huang, Z., Chen, K. N. et al. Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases. Cancer Res. 79, 7–20 (2019).
pubmed: 30389703
Yin, X., Jing, Y., Cai, M.-C., Ma, P., Zhang, Y., Xu, C. et al. Clonality, heterogeneity, and evolution of synchronous bilateral ovarian cancer. Cancer Res. 77, 6551–6561 (2017).
pubmed: 28972072
Patch, A. M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).
pubmed: 26017449
Ha, G., Roth, A., Khattra, J., Ho, J., Yap, D., Prentice, L. M. et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 24, 1881–1893 (2014).
pubmed: 25060187
pmcid: 4216928
Zhang, W., Liu, Y., Sun, N., Wang, D., Boyd-Kirkup, J., Dou, X. et al. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep. 4, 542–553 (2013).
pubmed: 23933257